Calcium Channel Blockers

Core Concepts

The role of calcium in the heart and vessels

Calcium ions (Ca²⁺) flow into cells through L-type voltage-gated calcium channels when the cell membrane depolarizes. The consequences differ by tissue:

• Vascular smooth muscle: calcium entry triggers contraction. More calcium → tighter vessels → higher systemic vascular resistance and blood pressure.
• Cardiac muscle: calcium links the electrical signal to physical contraction (excitation–contraction coupling). More calcium → stronger squeeze.
• SA and AV nodes: calcium currents drive the pacemaker's automatic firing and slow conduction through the AV node. The AV node depends heavily on calcium for conduction.

Blocking calcium entry therefore relaxes vessels, weakens contraction, slows the sinus node, and slows AV conduction — but each drug family emphasizes different parts of this menu.

Dihydropyridines: the vascular family

The DHPs (amlodipine, nifedipine, felodipine, nicardipine, isradipine, clevidipine) are vascular-selective: at usual doses they relax arterioles far more than they affect the heart. The results:

• Arteriolar vasodilation → lower systemic vascular resistance → lower blood pressure.
• Reduced afterload → the heart pushes against less resistance → less oxygen demand, which helps angina.
• Reflex tachycardia (a compensatory heart-rate increase) can occur, especially with short-acting agents; amlodipine's gradual onset makes this less prominent.

Uses: hypertension (very common), chronic stable angina, and sometimes Raynaud phenomenon (via vasodilation). The classic DHP side effects are ankle/foot edema (from arteriolar dilation raising capillary pressure — it is NOT the same as fluid overload), flushing, and headache.

Non-dihydropyridines: the cardiac family

Verapamil and diltiazem act mainly on the heart: they slow the SA node, slow AV conduction, and reduce contractility, with less pronounced vasodilation than DHPs.

• Verapamil: strong effects on the AV node and contractility; also relaxes vessels somewhat. Uses: hypertension, angina, and supraventricular tachycardias. Signature side effect: constipation (smooth-muscle relaxation in the gut).
• Diltiazem: intermediate between verapamil and the DHPs — slows the heart and AV conduction with moderate vasodilation. Uses: angina, rate control in atrial fibrillation, hypertension.

Because they depress the heart, the non-DHPs are used cautiously or avoided in people with significant heart failure with reduced ejection fraction or with sick sinus syndrome/high-grade AV block. Combining verapamil or diltiazem with a beta-blocker can cause profound bradycardia and should only occur under careful prescriber direction.

What CCBs do for angina and hypertension

• Angina: CCBs reduce myocardial oxygen demand (lower afterload, and for non-DHPs lower heart rate and contractility) and may improve coronary blood flow by relaxing coronary arteries and preventing coronary vasospasm — which makes them especially useful in vasospastic (Prinzmetal) angina.
• Hypertension: sustained vasodilation lowers systemic vascular resistance; DHPs are the usual first-choice CCB for blood pressure.
• Rate control: verapamil and diltiazem slow the ventricular rate in atrial fibrillation by slowing AV conduction.

Adverse effects and nursing vigilance

• Ankle/feet swelling (DHPs): common and dose-related; often more cosmetic than dangerous, but it should be assessed (it can also signal heart failure — check for other signs like dyspnea and weight gain).
• Flushing, headache, dizziness: vasodilation effects, especially early in therapy; orthostatic hypotension and fall risk should be assessed.
• Bradycardia, AV block (verapamil/diltiazem): especially when combined with beta-blockers; report dizziness, fainting, or unusually slow pulse.
• Constipation (verapamil): can be severe; encourage fluids, fiber, and activity per the person's overall health and provider guidance.
• Gingival (gum) overgrowth: reported with some CCBs; good oral hygiene and dental follow-up help.
• Grapefruit juice interaction: grapefruit juice inhibits drug metabolism and can raise blood levels of several CCBs — a classic teaching point. Discuss with the pharmacist/prescriber whether the person should avoid it entirely.

Person-first, scope-aware care

Talk about "a person with hypertension taking amlodipine," not "an amlodipine patient." Monitoring frequency, hold parameters, and who may initiate or titrate CCBs vary by guideline, state nurse practice act, and institutional policy. Educational content describes the class; actual doses, schedules, hold parameters, and decisions must always be verified against current references, the facility formulary, and the prescriber's orders.

Common Confusions